Novel, first-in-class, fatty acid synthase (FASN) inhibitor TVB-2640 demonstrates robust clinical efficacy and safety in a global phase 2 randomized placebo-controlled NASH trial (FASCINATE-1) conducted in the U.S. and China
AASLD The Liver Meeting
PUBLICATIONS
Translation of FASN Inhibitor TVB-2640 from Preclinical MOA to Clinical POC in NASH
NASH and Fibrosis Conference
Analysis of non-invasive biomarker tests in the Phase 2 FASCINATE-1 study of FASN inhibitor TVB-2640
EASL International Liver Congress
TVB-2640 with Bevacizumab in Relapsed High-grade Astrocytoma
European Society for Medical Oncology (ESMO) Congress
The FASN inhibitor TVB-2640 is efficacious in a new 3D human liver microtissue model of NASH
EASL International Liver Congress
